Oxygen Biotherapeutics Inc. (OXBT), a development stage biomedical company, Monday reported third-quarter net loss of $2.4 million or $0.14 per share, narrower than $7.3 million or $0.39 per share last year.
Total revenues of $222 thousand compared to $148 thousand last year.
For comments and feedback: editorial@rttnews.com